Beam Therapeutics Inc. (NASDAQ:BEAM) traded at $37.89 at last check on Friday, Oct 23, making an upward move of 6.7% on its previous day’s price.
Looking at the stock we see that its previous close was $35.51 and the beta (5Y monthly) reads 0 with the day’s price range being $34.60 – 38.37. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, BEAM has a high of $35.89 and a low of $13. The company’s stock has gained about 45.23% over that past 30 days.
Beam has a market cap of $2.01 Billion and is expected to release its quarterly earnings report on August 12, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the BEAM stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.56, with the EPS growth for the year raised at -$2.82 for 2020 and -$2.5 for next year. These figures represent -0.8% and at -0.11% growth in EPS for the two years respectively.
Based on estimates by 5 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Beam Therapeutics Inc. (BEAM) stock as a Hold, while 5 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the BEAM stock currently stands at 0, and the current price level is 33.8% off its SMA20 and 41.81% from its 50-day simple moving average. The RSI (14) is pointing at 71.23 while the volatility over the past week is 9.94% and drops to 8.55% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 2.75. The average price target for the stock over the next 12 months is $33.75, with the estimates having a low of $31 and a high of $40. These price ends are -18.18% and +5.57% off the current price level respectively, although investors could be excited at the prospect of a -15.55% if the BEAM share price touches on the median price of $32.
Let’s briefly compare Beam (BEAM) stock to its peers. We find that today’s price change of +6.7% and 0% over the past 12 months for BEAM competes that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -1.04% in the latest trading session and is +10.59% over the last one year. Another of its peers Amgen Inc (AMGN) has dropped -0.36% today, and is +11.87% up over the past year, while Gilead Sciences Inc (GILD) is also up 6.7% yet its price remains in the red at 0% over the same period. Bristol-Myers has a P/E ratio of 0 compared to Beam’s 0 and Amgen’s 18.56. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.34% and -0.1%, respectively, in early deals.
Coming back to Beam Therapeutics Inc. (NASDAQ:BEAM), we note that the average 3-month trading volume was 686.26 Million, while that of the preceding 10-day period stands at 788.21 Million. Current shares outstanding are 55.14 Million.
According to data from Thomson Reuters, insiders hold 13.61% of the company’s shares while institutions hold 23.31%. The data shows that short shares as of September 29, 2020, stood at 4.77 Million at a short ratio of 6.98. This represents a 9.5% Short interest in Shares outstanding on September 29, 2020. Shares short rose in September from the previous month at 3.35 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +102.08% up in year-to-date price movement.